Jefferies Financial Group Inc.
Position in NTLA — Intellia Therapeutics, Inc.
CIK 96223
NEW YORK, NY
Position in NTLA
as of Mar 31, 2026
· filed May 8, 2026
Position Value
$12,820
-$2,846 QoQ
Shares Held
1,000
+42.9% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
2 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NTLA Over Time
Shares Held
Position Value (USD)
Derivatives in NTLA
reported options exposure · as of Mar 31, 2026CallValue
$1,692,240
CallShares
132,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Mar 31, 2026Jefferies Financial Group Inc. holds $507,430,268 across 85 Biotechnology names. NTLA ranks #85 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PTCT |
Ptc Therapeutics, Inc.
|
1,354,459 | $92,279,291 | |
| 2 | IMTX |
Immatics N.V.
|
5,059,551 | $49,785,981 | |
| 3 | URGN |
UroGen Pharma Ltd.
|
2,199,652 | $39,549,742 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
175,599 | $33,196,990 | |
| 5 | BMRN |
Biomarin Pharmaceutical Inc
|
468,146 | $26,445,567 | |
| 6 | IMNM |
Immunome Inc.
|
1,160,715 | $25,384,837 | |
| 7 | ARGX |
Argenx SE
|
30,005 | $21,911,151 | |
| 8 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
202,410 | $16,986,247 |
All Filings in NTLA
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $12,820 | 1,000 | Shares | Defined | 2026-05-08 | |
| 2026-03-31 | $1,692,240 | 132,000 | Call | Defined | 2026-05-08 | |
| 2024-06-30 | $15,666 | 700 | Shares | Defined | 2024-08-13 | |
| 2024-06-30 | $223,800 | 10,000 | Call | Defined | 2024-08-13 | |
| No filing history on record for this holder in this stock. | ||||||